Aerovate Therapeutics
Tim has 30 years of industry experience leading all aspects of R&D and commercialization in the biopharmaceutical industry including Merck, Genzyme, and Proteon. He has extensive launch planning and commercial launch experience and at Genzyme, he headed all launch planning and the commercialization of Renagel, a treatment for hemodialysis patients that resulted in Genzyme’s acquisition of GelTex for more than $1 billion.
This person is not in any offices